A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Carbidopa (Primary) ; Droxidopa (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Chelsea Therapeutics
- 22 Dec 2011 Top-line results have been presented in a Chelsea Therapeutics media release.
- 03 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Aug 2011 Planned End Date changed from 1 Dec 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.